Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus KANUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus KANUMA.
ALDURAZYME vs KANUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
0.58 mg/kg administered intravenously once weekly.
1 mg/kg intravenously over 4 hours once weekly.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy